Discontinued — last reported Q3 '25
Litigation settlement gain (loss)
Incyte Litigation settlement gain (loss) decreased by 100.0% to $0 in Q3 2025 compared to the prior quarter.
Analysis
How to read this metric
Gains provide a one-time boost to net income, while losses represent unexpected cash outflows and potential reputational or operational risks.
Detailed definition
This metric captures the financial impact of legal settlements, including payments made to resolve disputes or proceeds...
Peer comparison
Common in the pharmaceutical industry due to patent litigation and regulatory challenges; often treated as an 'adjusted' item by analysts.
pfe_litigation_settlement_gain_lossHistorical Data
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $242.25M | $0 |
| QoQ Change | — | — | — | — | — | — | — | — | — | -100.0% |
Product Breakdown
| Segment | Q2 '25 |
|---|---|
| JAKAFI | $242.2M |
| Total | $242.25M |
JAKAFI was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Business Segments
| Segment | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q2 '25 | Q3 '25 |
|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $0 | $0 | $0 | $0 | $0 | $0 | $242.25M | $0 |
| Total | $0 | $0 | $0 | $0 | $0 | $0 | $242.25M | $0 |
Reportable Segment was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Litigation settlement gain (loss) at Other Companies
Frequently Asked Questions
- What is Incyte's litigation settlement gain (loss)?
- Incyte (INCY) reported litigation settlement gain (loss) of $0 in Q3 2025.
- What does litigation settlement gain (loss) mean?
- Financial gains or losses resulting from the resolution of legal disputes.